{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T01:42:45Z","timestamp":1774921365471,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10067-022-06096-0","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T16:24:18Z","timestamp":1644855858000},"page":"1659-1663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors"],"prefix":"10.1007","volume":"41","author":[{"given":"Wonho","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Keun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-3124","authenticated-orcid":false,"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"6096_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI (2013) Clinical practice: herpes zoster. N Engl J Med 369:255\u2013263","journal-title":"N Engl J Med"},{"key":"6096_CR2","doi-asserted-by":"publisher","first-page":"k5095","DOI":"10.1136\/bmj.k5095","volume":"364","author":"P Le","year":"2019","unstructured":"Le P, Rothberg M (2019) Herpes zoster infection. BMJ 364:k5095","journal-title":"BMJ"},{"key":"6096_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","volume":"4","author":"SL Thomas","year":"2004","unstructured":"Thomas SL, Hall AJ (2004) What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4:26\u201333","journal-title":"Lancet Infect Dis"},{"key":"6096_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA et al (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57:1431\u20131438","journal-title":"Arthritis Rheum"},{"key":"6096_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0961203312470186","volume":"22","author":"EF Chakravarty","year":"2013","unstructured":"Chakravarty EF, Michaud K, Katz R, Wolfe F (2013) Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus 22:238\u2013244","journal-title":"Lupus"},{"key":"6096_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","volume":"4","author":"G Gupta","year":"2006","unstructured":"Gupta G, Lautenbach E, Lewis JD (2006) Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4:1483\u20131490","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6096_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/acr.21928","volume":"65","author":"BM Veetil","year":"2013","unstructured":"Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS (2013) Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 65:854\u2013861","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6096_CR8","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1086\/598331","volume":"48","author":"JR McDonald","year":"2009","unstructured":"McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE et al (2009) Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 48:1364\u20131371","journal-title":"Clin Infect Dis"},{"key":"6096_CR9","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"M Harigai","year":"2019","unstructured":"Harigai M (2019) Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 58:i34\u2013i42","journal-title":"Rheumatology (Oxford)"},{"key":"6096_CR10","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S et al (2014) Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66:2675\u20132684","journal-title":"Arthritis Rheumatol"},{"key":"6096_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R et al (2020) Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis 79:1290\u20131297","journal-title":"Ann Rheum Dis"},{"key":"6096_CR12","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393:2303\u20132311","journal-title":"Lancet"},{"key":"6096_CR13","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75:1843\u20131847","journal-title":"Ann Rheum Dis"},{"key":"6096_CR14","doi-asserted-by":"crossref","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L et al (2020) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80:304-311","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"6096_CR15","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H et al (2017) Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 69:1960\u20131968","journal-title":"Arthritis Rheumatol"},{"key":"6096_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/14397595.2019.1583711","volume":"30","author":"M Harigai","year":"2020","unstructured":"Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP et al (2020) Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phases 2 and 3 trials. Mod Rheumatol 30:36\u201343","journal-title":"Mod Rheumatol"},{"key":"6096_CR17","doi-asserted-by":"publisher","first-page":"1759720X2093605","DOI":"10.1177\/1759720X20936059","volume":"12","author":"F Sunzini","year":"2020","unstructured":"Sunzini F, McInnes I, Siebert S (2020) JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis 12:1759720X20936059","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"6096_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/acr.23769","volume":"71","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H et al (2019) Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res (Hoboken) 71:1249\u20131254","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6096_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS et al (2022) Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis 81:206\u2013213","journal-title":"Ann Rheum Dis"},{"key":"6096_CR20","doi-asserted-by":"crossref","unstructured":"Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL et al (2021) Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther 9:243-263","DOI":"10.1007\/s40744-021-00390-0"},{"key":"6096_CR21","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ (2014) Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4:e004833","journal-title":"BMJ Open"},{"key":"6096_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/cei.12809","volume":"187","author":"N Arnold","year":"2017","unstructured":"Arnold N, Messaoudi I (2017) Herpes zoster and the search for an effective vaccine. Clin Exp Immunol 187:82\u201392","journal-title":"Clin Exp Immunol"},{"key":"6096_CR23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s12325-016-0355-0","volume":"33","author":"F Ansaldi","year":"2016","unstructured":"Ansaldi F, Trucchi C, Alicino C, Paganino C, Orsi A, Icardi G (2016) Real-world effectiveness and safety of a live-attenuated herpes zoster vaccine: a comprehensive review. Adv Ther 33:1094\u20131104","journal-title":"Adv Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06096-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:59:15Z","timestamp":1659059955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06096-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6096"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06096-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"14 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}